

RECEIVED
CENTRAL FAX CENTER

JUN 01 2005

Genzyme Corporation

500 Kendall Street, 10th Floor
Cambridge, Massachusetts 02142 U.S.A.
Telephone: (617) 252-7500
Facsimile: (617) 252-7553

LEGAL DEPARTMENT

Jennifer L. Dupré
Direct Dial: (617) 768-6523
jennifer.dupre@genzyme.com

Facsimile

To:	Commissioner for Patents	From:	Jennifer L. Dupré
Fax:	(703) 872-9306	Pages:	12
Phone:		Date:	6/1/2005
Re:	Attorney Docket No. GC22.4-CON2	CC:	
Appln No.:	10/814,025		
Filing Date:	March 31, 2004		
Title:	ENZYMATICALLY ACTIVE RECOMBINANT GLUCOCEREBROSIDASE		

RECEIVED
JUN - 2 2005
OIPE/JCWS

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the addressee(s) listed above, and may contain information that is confidential or privileged. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If this message was received in error, please telephone us immediately.

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office

on June 1, 2005.

Date

Deborah A. Gunkel

Signature

Deborah A. Gunkel

Typed or printed name of person signing Certificate

Registration Number if applicable

(617) 768-6653

Telephone Number

Note: Each paper must have its own certificate of transmission, or this
certificate must identify each submitted paper.

Amendment and Response to Restriction Requirement, 8 pages;
Petition for Extension of Time Under 37 CFR 1.136(a), 1 page (in duplicate).

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ATTORNEY DOCKET GC22.4-CON2**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Rasmussen et al.
Serial Number: 10/814,025
Filing Date: March 31, 2004
Examiner: Sullivan, Daniel M.
Group No.: 1636
Title: ENZYMATICALLY ACTIVE RECOMBINANT
GLUCOCEREBROSIDASE

Commissioner for Patents
P.O. Box 1450
Washington, D.C. 20231

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is responsive to the Office Action mailed from the Patent Office on March 18, 2005. Applicants hereby petition concurrently herewith to extend the time for response and have paid the required fee.

Amendment to the Claims are reflected in the listing claims which begin on page 2 of this paper.

Remarks begin on page 5 of this paper.